Relapsing Remitting Multiple Sclerosis News and Research

RSS
Phase III study of BG-12 in relapsing-remitting multiple sclerosis sparks excitement

Phase III study of BG-12 in relapsing-remitting multiple sclerosis sparks excitement

Biogen Idec third quarter revenues increase 11% to $1.3 billion

Biogen Idec third quarter revenues increase 11% to $1.3 billion

Abbott, Biogen Idec announce additional results from daclizumab HYP Phase 2b trial for RRMS

Abbott, Biogen Idec announce additional results from daclizumab HYP Phase 2b trial for RRMS

Sanofi announces new results from alemtuzumab-Rebif comparative CARE-MS I trial

Sanofi announces new results from alemtuzumab-Rebif comparative CARE-MS I trial

Genentech announces 96-week results from ocrelizumab Phase II study on RRMS

Genentech announces 96-week results from ocrelizumab Phase II study on RRMS

COPAXONE reduces loss of brain volume in patients with RRMS

COPAXONE reduces loss of brain volume in patients with RRMS

Positive top-line results from alemtuzumab Phase 3 trial on multiple sclerosis

Positive top-line results from alemtuzumab Phase 3 trial on multiple sclerosis

Scientists discover molecular mechanism that could help develop new MS treatments

Scientists discover molecular mechanism that could help develop new MS treatments

Teva completes patient enrollment in COPAXONE Phase III trial for treatment of multiple sclerosis

Teva completes patient enrollment in COPAXONE Phase III trial for treatment of multiple sclerosis

Decision Resources: 63% of neurologists select Tysabri as effective MS treatment

Decision Resources: 63% of neurologists select Tysabri as effective MS treatment

Biogen Idec first quarter revenues increase 9% to $1.2 billion

Biogen Idec first quarter revenues increase 9% to $1.2 billion

Genzyme reports positive data from 5-year alemtuzumab Phase 2 study in MS

Genzyme reports positive data from 5-year alemtuzumab Phase 2 study in MS

Teva presents new CNS products study data in RRMS, Parkinson's at AAN meeting

Teva presents new CNS products study data in RRMS, Parkinson's at AAN meeting

Positive top-line results from Biogen BG-12 Phase 3 trial in RRMS

Positive top-line results from Biogen BG-12 Phase 3 trial in RRMS

Gilenya can reduce risk of disability progression in patients with RRMS

Gilenya can reduce risk of disability progression in patients with RRMS

Genzyme's alemtuzumab Phase 2 trial data in MS to be presented at AAN meeting

Genzyme's alemtuzumab Phase 2 trial data in MS to be presented at AAN meeting

Adeona reports $3,164,512 net revenue for 2010

Adeona reports $3,164,512 net revenue for 2010

Opexa's Tovaxin data against MS to be presented at AAN Annual Meeting

Opexa's Tovaxin data against MS to be presented at AAN Annual Meeting

EMD Serono receives FDA CRL on Cladribine Tablets NDA for relapsing-remitting multiple sclerosis

EMD Serono receives FDA CRL on Cladribine Tablets NDA for relapsing-remitting multiple sclerosis

Pill for multiple sclerosis in the pipeline

Pill for multiple sclerosis in the pipeline